{"id":9855,"date":"2024-04-18T15:55:32","date_gmt":"2024-04-18T13:55:32","guid":{"rendered":"https:\/\/www.geicogroup.com\/ensayos-clinicos\/"},"modified":"2026-07-10T12:21:03","modified_gmt":"2026-07-10T10:21:03","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/www.geicogroup.com\/en\/research\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"9855\" class=\"elementor elementor-9855 elementor-5761\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4db3e1c e-con-full e-flex e-con e-parent\" data-id=\"4db3e1c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-eb1eaea e-con-full e-flex e-con e-child\" data-id=\"eb1eaea\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-15d5445 elementor-widget-tablet__width-initial elementor-widget elementor-widget-heading\" data-id=\"15d5445\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Clinical Trials<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4beeecc e-con-full e-flex e-con e-parent\" data-id=\"4beeecc\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fd24b7b elementor-widget__width-inherit elementor-widget elementor-widget-html\" data-id=\"fd24b7b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<svg style=\"display:none\" aria-hidden=\"true\">\r\n    <symbol id=\"icon-flecha\" viewBox=\"0 0 11 10\">\r\n        <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\r\n    <\/symbol>\r\n<\/svg>\r\n<div class=\"container-ensayos\"><div id=\"filters-container\" class=\"filters-container\"><div class=\"w-100 d-flex flex-column parte_filtro\">\r\n\r\n    <div class=\"col-12 principales mb-3 d-flex flex-wrap justify-content-between align-items-center\">\r\n        <span class=\"col-8\">Abiertos<\/span>\r\n        <button id=\"limpia_abiertos\" class=\"col-4\" type=\"button\">\r\n            <svg width=\"30\" height=\"20\" viewBox=\"0 0 89 87\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\r\n                <path d=\"M72.386 64.3533C69.4669 65.0602 66.8328 65.7121 64.192 66.3341C60.997 67.0864 58.5584 64.9868 58.8093 61.7219C58.946 59.9434 60.1129 58.6595 62.1068 58.1772C66.3082 57.1615 70.5159 56.1717 74.7207 55.1697C76.2178 54.8131 77.7137 54.4499 79.2114 54.0947C81.782 53.4845 83.9805 54.8097 84.5964 57.3611C85.9797 63.0907 87.3583 68.8213 88.7239 74.5551C89.333 77.1126 88.1104 79.1812 85.6899 79.7521C83.1766 80.3452 81.189 79.0844 80.5515 76.4791C80.0163 74.2916 79.4956 72.1007 78.9284 69.7444C78.1053 70.6638 77.4191 71.4772 76.6844 72.244C66.8494 82.5077 54.8175 87.2589 40.6531 86.2065C21.3179 84.7701 4.738 69.9716 1.00025 51.0383C0.721494 49.6261 0.4856 48.1965 0.365418 46.7635C0.154507 44.2528 1.74423 42.341 4.11605 42.1132C6.43555 41.8905 8.35373 43.4316 8.65537 45.8957C9.58107 53.4617 12.3679 60.2263 17.5105 65.8791C25.3868 74.5367 35.2307 78.6111 46.936 77.8184C56.8798 77.1452 65.0706 72.8386 71.601 65.3366C71.8121 65.0938 72.0033 64.8337 72.3857 64.353L72.386 64.3533Z\"\/>\r\n                <path d=\"M16.7059 21.7763C18.8492 21.2614 20.9736 20.7512 23.0979 20.2408C23.6712 20.103 24.2417 19.9523 24.8178 19.8292C27.1965 19.3211 29.2046 20.5976 29.795 22.9844C30.361 25.2719 29.1499 27.3681 26.8268 27.9866C24.7702 28.5341 22.6909 28.9946 20.6212 29.4919C16.9913 30.3642 13.3642 31.2481 9.73009 32.103C6.97247 32.7518 4.91754 31.5108 4.24693 28.7674C2.84761 23.0415 1.46328 17.3117 0.108136 11.575C-0.333935 9.70337 0.614901 7.8149 2.30613 6.96653C3.99658 6.11867 6.0828 6.51946 7.34091 7.92825C7.95181 8.61226 8.2261 9.44223 8.42965 10.3137C8.89644 12.3121 9.38006 14.3063 9.89393 16.4567C10.6111 15.6491 11.2241 14.9383 11.8589 14.2474C18.4553 7.06882 26.6758 2.88453 36.1337 0.820658C55.0917 -3.31656 82.3045 8.18597 87.8833 35.3987C88.1266 36.5848 88.2599 37.7934 88.4456 38.9913C88.8711 41.7347 87.5107 43.7802 85.0229 44.1371C82.3194 44.5247 80.4163 42.9515 80.0967 40.0745C79.6778 36.3005 78.754 32.649 77.1001 29.2318C71.3237 17.2969 61.8969 10.1354 48.7097 8.54126C36.125 7.01991 25.596 11.3836 17.1974 20.8748C17.0241 21.0705 16.8648 21.279 16.7101 21.4899C16.6812 21.5294 16.7059 21.608 16.7059 21.7763Z\"\/>\r\n            <\/svg> \r\n        <\/button>\r\n    <\/div>\r\n\r\n    <div class=\"col-12 d-flex flex-column justify-content-center align-items-center gap-3 my-3\">\r\n        <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-reclutamiento\" value=\"reclutamiento\" autocomplete=\"off\" \/>\r\n        <label class=\"filter-type option-1\" for=\"option-reclutamiento\">Reclutamiento<\/label>\r\n\r\n        <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-startup\" value=\"start-up\" autocomplete=\"off\" \/>\r\n        <label class=\"filter-type option-2\" for=\"option-startup\">Start Up<\/label>\r\n\r\n        <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-seguimiento\" value=\"seguimiento\" autocomplete=\"off\" \/>\r\n        <label class=\"filter-type option-3\" for=\"option-seguimiento\">Seguimiento<\/label>\r\n    <\/div>\r\n\r\n            <div class=\"col-12 my-3 d-flex flex-column\">\r\n            <span class=\"titulo_filtro\">Ovario<\/span>\r\n\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_ovario_1a-linea\"\r\n                               data-filter-key=\"ovario:1a-linea\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_ovario_1a-linea\">\r\n                            1\u00aa L\u00ednea                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_ovario_recaida\"\r\n                               data-filter-key=\"ovario:recaida\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_ovario_recaida\">\r\n                            Reca\u00edda                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                    <\/div>\r\n            <div class=\"col-12 my-3 d-flex flex-column\">\r\n            <span class=\"titulo_filtro\">C\u00e9rvix<\/span>\r\n\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_cervix_localmente-avanzado\"\r\n                               data-filter-key=\"cervix:localmente-avanzado\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_cervix_localmente-avanzado\">\r\n                            Localmente Avanzado                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_cervix_metastasico\"\r\n                               data-filter-key=\"cervix:metastasico\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_cervix_metastasico\">\r\n                            Metast\u00e1sico                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                    <\/div>\r\n            <div class=\"col-12 my-3 d-flex flex-column\">\r\n            <span class=\"titulo_filtro\">Endometrio<\/span>\r\n\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_endometrio_localizado\"\r\n                               data-filter-key=\"endometrio:localizado\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_endometrio_localizado\">\r\n                            Localizado                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_endometrio_avanzado\"\r\n                               data-filter-key=\"endometrio:avanzado\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_endometrio_avanzado\">\r\n                            Avanzado                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                    <\/div>\r\n            <div class=\"col-12 my-3 d-flex flex-column\">\r\n            <span class=\"titulo_filtro\">Otros<\/span>\r\n\r\n                            <div class=\"col-12 secundarios mt-3\">\r\n                    <div class=\"form-check\">\r\n                        <input class=\"form-check-input\" type=\"checkbox\"\r\n                               id=\"check_otros_quirurgico\"\r\n                               data-filter-key=\"otros:quirurgico\" \/>\r\n                        <label class=\"form-check-label\" for=\"check_otros_quirurgico\">\r\n                            Quir\u00fargico                        <\/label>\r\n                    <\/div>\r\n                <\/div>\r\n                    <\/div>\r\n    \r\n<\/div>\r\n\r\n<div class=\"w-100 d-flex flex-column parte_filtro\">\r\n\r\n    <span class=\"col-12 close-cancel mb-3\">Cerrados | Cancelados<\/span>\r\n\r\n    <div class=\"col-12 d-flex flex-wrap my-3 gap-2\">\r\n        <input type=\"radio\" class=\"btn-check filters-cerrados\" name=\"options_closed\" id=\"option-cerrado\" value=\"cerrado\" autocomplete=\"off\" \/>\r\n        <label class=\"filter-type option-4\" for=\"option-cerrado\">Cerrados<\/label>\r\n\r\n        <input type=\"radio\" class=\"btn-check filters-cerrados\" name=\"options_closed\" id=\"option-cancelado\" value=\"cancelado\" autocomplete=\"off\" \/>\r\n        <label class=\"filter-type option-5\" for=\"option-cancelado\">Cancelados<\/label>\r\n    <\/div>\r\n\r\n            <div class=\"col-12 secundarios mt-3\">\r\n            <div class=\"form-check\">\r\n                <input class=\"form-check-input\" type=\"checkbox\"\r\n                       id=\"check_cerrados_ovario\"\r\n                       data-filter-tipo-cerrado=\"ovario\" \/>\r\n                <label class=\"form-check-label\" for=\"check_cerrados_ovario\">\r\n                    C\u00e1ncer de Ovario                <\/label>\r\n            <\/div>\r\n        <\/div>\r\n            <div class=\"col-12 secundarios mt-3\">\r\n            <div class=\"form-check\">\r\n                <input class=\"form-check-input\" type=\"checkbox\"\r\n                       id=\"check_cerrados_cervix\"\r\n                       data-filter-tipo-cerrado=\"cervix\" \/>\r\n                <label class=\"form-check-label\" for=\"check_cerrados_cervix\">\r\n                    C\u00e1ncer de C\u00e9rvix                <\/label>\r\n            <\/div>\r\n        <\/div>\r\n            <div class=\"col-12 secundarios mt-3\">\r\n            <div class=\"form-check\">\r\n                <input class=\"form-check-input\" type=\"checkbox\"\r\n                       id=\"check_cerrados_endometrio\"\r\n                       data-filter-tipo-cerrado=\"endometrio\" \/>\r\n                <label class=\"form-check-label\" for=\"check_cerrados_endometrio\">\r\n                    C\u00e1ncer de Endometrio                <\/label>\r\n            <\/div>\r\n        <\/div>\r\n    \r\n<\/div>\r\n<\/div> <div id=\"contenido_filtros\" class=\"ensayos\"><div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov62\/GEICO 129-O\/N-Plus        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Purificaci\u00f3n Estevez<\/span>\r\n\r\n                                    <span>CoPI: Arantzazu Barquin<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase II randomized, open label non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked  advanced HRDpositive high-grade ovarian cancer patientS in first line therapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov62\/GEICO 129-O\/N-Plus\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov62_GEICO%20129-O_N-Plus\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05460000\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2024 - oct 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV63\/GEICO 110-0\/NIRVANA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized Study of Paclitaxel \u2013 Carboplatin followed by maintenance Niraparib versus Paclitaxel \u2013 Carboplatin \u2013 Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-OV63\/GEICO 110-0\/NIRVANA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-OV63_GEICO%20110-0_NIRVANA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-004278-76\/ES\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    nov 2022 - mar 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov84\/GEICO 141-O\/MK-2870-022\/TROFUSE-022-EvoPAR Ovarian01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.MK-2870\/022-PARPi (EvoPAR Ovarian01)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov84\/GEICO 141-O\/MK-2870-022\/TROFUSE-022-EvoPAR Ovarian01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov84_GEICO%20141-O_MK-2870-022_TROFUSE-022-EvoPAR%20Ovarian01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    ene 2026 - mar 2028                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV85\/GEICO 151-O\/MK-2870-021 \/TROFUSE-021        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez-Fidalgo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cPhase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy.GINECO\/MK-2870-021            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-OV85\/GEICO 151-O\/MK-2870-021 \/TROFUSE-021\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-OV85_GEICO%20151-O_MK-2870-021%20_TROFUSE-021\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    mar 2026 - ago 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV89\/GEICO 144-O\/DESTINY-OVARIAN 01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Luis Manso<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer.DESTINY-OVARIAN 01            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-OV89\/GEICO 144-O\/DESTINY-OVARIAN 01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-OV89_GEICO%20144-O_DESTINY-OVARIAN%2001\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    dic 2025 - sep 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov105\/GEICO 195-O\/BEHOLD-Ovarian03        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ra\u00fal M\u00e1rquez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov105\/GEICO 195-O\/BEHOLD-Ovarian03\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov105_GEICO%20195-O_BEHOLD-Ovarian03\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV57\/GEICO 109-O\/AGO-OVAR 28        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Lydia Gaba<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-OV57\/GEICO 109-O\/AGO-OVAR 28\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-OV57_GEICO%20109-O_AGO-OVAR%2028\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov106\/MAESTRA3        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov106\/MAESTRA3\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov106_MAESTRA3\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov107\/REJOICE Ovarian05\/MK5909-008        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Lydia Gaba<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov107\/REJOICE Ovarian05\/MK5909-008\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov107_REJOICE%20Ovarian05_MK5909-008\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov45\/GEICO 74-O\/ATHENA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov45\/GEICO 74-O\/ATHENA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov45_GEICO%2074-O_ATHENA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03522246\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"1a-linea\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>1\u00aa L\u00ednea<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov43\/GEICO 80-O\/7339-001        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"1\u00aa L\u00ednea\"\r\n                        data-name=\"ENGOT-ov43\/GEICO 80-O\/7339-001\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/1a-linea\/ENGOT-ov43_GEICO%2080-O_7339-001\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03740165\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT ov77\/GEICO 136-O\/REJOICE-ovarian 01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Lydia Gaba<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 2\/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT ov77\/GEICO 136-O\/REJOICE-ovarian 01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT%20ov77_GEICO%20136-O_REJOICE-ovarian%2001\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=NCT06161025\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov81\/GEICO 154-O\/RAMP 301        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator\u2019s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov81\/GEICO 154-O\/RAMP 301\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov81_GEICO%20154-O_RAMP%20301\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05460000\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov84\/GEICO 141-O\/MK-2870-022        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov84\/GEICO 141-O\/MK-2870-022\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov84_GEICO%20141-O_MK-2870-022\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06824467\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov83\/GEICO 146-O\/CATALINA-2\/TORL        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cA Phase 2 study evaluating the efficacy and safety of TORL-1-23 in Women with advanced platinum-resistant epithelial ovarian cancer (including primary peritoneal and fallopian tube cancers) expressing Claudin 6 (CLdn6)\u201d NOGGO\/TORL            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov83\/GEICO 146-O\/CATALINA-2\/TORL\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov83_GEICO%20146-O_CATALINA-2_TORL\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06824467\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    nov 2025 - sep 2026                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            APGOT-ov14\/GEICO 169-O\/TROY        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Cort\u00e9s<\/span>\r\n\r\n                                    <span>CoPI: A. Madariaga<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"APGOT-ov14\/GEICO 169-O\/TROY\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/APGOT-ov14_GEICO%20169-O_TROY\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2026 - oct 2030                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov101\/GEICO 176-O\/NAPISTAR 3-01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Pau Guill\u00e9n<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov101\/GEICO 176-O\/NAPISTAR 3-01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov101_GEICO%20176-O_NAPISTAR%203-01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    sep 2026 - mar 2028                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov102\/GEICO 181-O\/REJOICE-Ovarian 04        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Luis Manso<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov102\/GEICO 181-O\/REJOICE-Ovarian 04\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov102_GEICO%20181-O_REJOICE-Ovarian%2004\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOTov103\/GEICO 177-O\/RAINFOL-07        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                    <span>CoPI: Pablo Andreu Cobo<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOTov103\/GEICO 177-O\/RAINFOL-07\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOTov103_GEICO%20177-O_RAINFOL-07\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2026 - nov 2028                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov104\/GEICO 192-O\/REJOICE-Ovarian 03        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov104\/GEICO 192-O\/REJOICE-Ovarian 03\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov104_GEICO%20192-O_REJOICE-Ovarian%2003\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2026 - sep 2029                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov93\/GEICO 170-O\/TREVI        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Lydia Gaba<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov93\/GEICO 170-O\/TREVI\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov93_GEICO%20170-O_TREVI\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov94\/GEICO 171-O\/INCB123667-203        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov94\/GEICO 171-O\/INCB123667-203\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov94_GEICO%20171-O_INCB123667-203\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov95\/GEICO 172-O\/INCB 123667-305        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov95\/GEICO 172-O\/INCB 123667-305\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov95_GEICO%20172-O_INCB%20123667-305\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov96\/GEICO 173-O\/GCT1184-04 (RAINFOL-04)        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov96\/GEICO 173-O\/GCT1184-04 (RAINFOL-04)\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov96_GEICO%20173-O_GCT1184-04%20(RAINFOL-04)\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov97\/GEICO 174-O\/FRAmework-01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Fernando G\u00e1lvez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov97\/GEICO 174-O\/FRAmework-01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov97_GEICO%20174-O_FRAmework-01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov98\/GEICO 175-O\/BEHOLD-OVARIAN 01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Yolanda Garc\u00eda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov98\/GEICO 175-O\/BEHOLD-OVARIAN 01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov98_GEICO%20175-O_BEHOLD-OVARIAN%2001\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov99\/GEICO 180-O\/BEHOLD-OVARIAN 02        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov99\/GEICO 180-O\/BEHOLD-OVARIAN 02\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov99_GEICO%20180-O_BEHOLD-OVARIAN%2002\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov109\/ASPENOVA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro Mart\u00ednez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov109\/ASPENOVA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov109_ASPENOVA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov76\/GEICO 127-O\/GLORIOSA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: M\u00aa Jes\u00fas Bermejo<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized Phase 3 Trial for Mirvetuximab + Bevatuximab manteinance in FR@High PSOC Patients            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov76\/GEICO 127-O\/GLORIOSA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov76_GEICO%20127-O_GLORIOSA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05445778\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT gyn5\/GEICO 131-O\/NXP 800        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT gyn5\/GEICO 131-O\/NXP 800\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT%20gyn5_GEICO%20131-O_NXP%20800\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05226507?term=nxp800&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 114-O\/ART0380C001        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Mar\u00eda Quind\u00f3s<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase I\/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"GEICO 114-O\/ART0380C001\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/GEICO%20114-O_ART0380C001\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04657068\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT ov72\/GEICO 122-O\/ROSELLA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator\u2019s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT ov72\/GEICO 122-O\/ROSELLA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT%20ov72_GEICO%20122-O_ROSELLA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT05257408?V_1=View\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov61\/GEICO 96-O\/EPIK-O        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov61\/GEICO 96-O\/EPIK-O\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov61_GEICO%2096-O_EPIK-O\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04729387\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov55\/GEICO 91-O\/MIRASOL        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Yolanda Garc\u00eda<\/span>\r\n\r\n                                    <span>CoPI: Paula Guill\u00e9n<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator\u2019s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov55\/GEICO 91-O\/MIRASOL\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov55_GEICO%2091-O_MIRASOL\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04209855\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov67\/GEICO 106-O\/UPLIFT        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez Fidalgo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 1b\/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov67\/GEICO 106-O\/UPLIFT\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov67_GEICO%20106-O_UPLIFT\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03319628\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov50\/GEICO 82-O\/INNOVATE 3        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov50\/GEICO 82-O\/INNOVATE 3\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov50_GEICO%2082-O_INNOVATE%203\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03940196\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov68\/GEICO 112-O\/ARTISTRY-7        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator\u2019s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)\u201d            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-ov68\/GEICO 112-O\/ARTISTRY-7\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-ov68_GEICO%20112-O_ARTISTRY-7\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"recaida\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Ovario<\/span>\r\n                <span>Reca\u00edda<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV86\/GEICO 152-O\/RAINFOL-OV2        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Mar\u00eda Quind\u00f3s<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cA Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator\u2019s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer\u201dRAINFOL-OV2            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Ovario\"\r\n                        data-subtype=\"Reca\u00edda\"\r\n                        data-name=\"ENGOT-OV86\/GEICO 152-O\/RAINFOL-OV2\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/ovario\/recaida\/ENGOT-OV86_GEICO%20152-O_RAINFOL-OV2\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2025 - feb 2026                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"localmente-avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Localmente Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 78-C\/ATOMICC        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Roberta Mazzeo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Localmente Avanzado\"\r\n                        data-name=\"GEICO 78-C\/ATOMICC\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/localmente-avanzado\/GEICO%2078-C_ATOMICC\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03833479\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    jul 2019 - jul 2023                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"localmente-avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Localmente Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx12\/GEICO 84-C\/GCT1015-07        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Jer\u00f3nimo Mart\u00ednez Garc\u00eda<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator\u2019s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer\u201d            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Localmente Avanzado\"\r\n                        data-name=\"ENGOT-cx12\/GEICO 84-C\/GCT1015-07\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/localmente-avanzado\/ENGOT-cx12_GEICO%2084-C_GCT1015-07\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04221945\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"localmente-avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Localmente Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx11\/GEICO 86-C\/MK3475-A18        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer\u201d            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Localmente Avanzado\"\r\n                        data-name=\"ENGOT-cx11\/GEICO 86-C\/MK3475-A18\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/localmente-avanzado\/ENGOT-cx11_GEICO%2086-C_MK3475-A18\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=engot%20cx8\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"localmente-avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Localmente Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx8\/GEICO 113-C\/TV205        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg\/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Localmente Avanzado\"\r\n                        data-name=\"ENGOT-cx8\/GEICO 113-C\/TV205\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/localmente-avanzado\/ENGOT-cx8_GEICO%20113-C_TV205\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03786081?term=NCT03786081&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"metastasico\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Metast\u00e1sico<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx19\/GEICO 133-C\/eVolve-Cervical        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Metast\u00e1sico\"\r\n                        data-name=\"ENGOT-cx19\/GEICO 133-C\/eVolve-Cervical\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/metastasico\/ENGOT-cx19_GEICO%20133-C_eVolve-Cervical\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    sep 2024 - dic 2026                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"metastasico\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Metast\u00e1sico<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx22\/GEICO 185-C\/TroFuse-036        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Lorena Fari\u00f1as<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Metast\u00e1sico\"\r\n                        data-name=\"ENGOT-cx22\/GEICO 185-C\/TroFuse-036\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/metastasico\/ENGOT-cx22_GEICO%20185-C_TroFuse-036\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"metastasico\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>C\u00e9rvix<\/span>\r\n                <span>Metast\u00e1sico<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT cx20\/GEICO 138-C\/MK2870-020        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                    <span>CoPI: Luis Manso<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic  Cervical Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"C\u00e9rvix\"\r\n                        data-subtype=\"Metast\u00e1sico\"\r\n                        data-name=\"ENGOT cx20\/GEICO 138-C\/MK2870-020\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/cervix\/metastasico\/ENGOT%20cx20_GEICO%20138-C_MK2870-020\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03786081?term=NCT03786081&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"localizado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Localizado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 137-E\/NADIA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez-Fidalgo<\/span>\r\n\r\n                                    <span>CoPI: Lydia Gaba<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                PHASE II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd\/MSI-H stage II-III endometrial cancer.NADIA            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Localizado\"\r\n                        data-name=\"GEICO 137-E\/NADIA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/localizado\/GEICO%20137-E_NADIA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"localizado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Localizado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN2\/GEICO 47-E        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Santaballa<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. A Phase II, multicenter, prospective, open-label, randomized, controlled study.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Localizado\"\r\n                        data-name=\"ENGOT-EN2\/GEICO 47-E\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/localizado\/ENGOT-EN2_GEICO%2047-E\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN28\/GEICO 160-E\/Bluestar-Endometrial01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Marta Gil<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase III, Randomized, Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus treatment of Physician\u00b4s choice in Participants with B7-H4-Selected Advanced\/Metastatic Endometrial Cancer who progress after Platinum-based Chemotherapy and Anti PD-1\/anti-PD-L1 therapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN28\/GEICO 160-E\/Bluestar-Endometrial01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN28_GEICO%20160-E_Bluestar-Endometrial01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    ago 2025 - oct 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN25\/GEICO 153-E\/BNT 323-01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Jes\u00fas Rubio<\/span>\r\n\r\n                                    <span>CoPI: Cristina Churruca<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cA Phase III, randomized, multi-site, open-label trial of BNT323\/DB-1303 versus investigator\u2019s choice of chemotherapy in previously treated patients with HER2-expressing recurrent or metastatic endometrial cancer.\u201d            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN25\/GEICO 153-E\/BNT 323-01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN25_GEICO%20153-E_BNT%20323-01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    may 2025 - dic 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN24\/GEICO 147-E\/DESTINY        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+\/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer\u201d(DESTINY)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN24\/GEICO 147-E\/DESTINY\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN24_GEICO%20147-E_DESTINY\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2025 - dic 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN30\/GEICO 161-E\/DESTINY Endometrial 02        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Mar\u00eda Quind\u00f3s<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan versus Standard of Care (Carboplatin in Combination with Paclitaxel) as Adjuvant Treatment for HER2-expressing (IHC 3+\/IHC 2+) Endometrial Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN30\/GEICO 161-E\/DESTINY Endometrial 02\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN30_GEICO%20161-E_DESTINY%20Endometrial%2002\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    abr 2026 - abr 2029                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en31\/GEICO 158-E\/RAINFOL 03        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ant\u00f3nio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator\u2019s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en31\/GEICO 158-E\/RAINFOL 03\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en31_GEICO%20158-E_RAINFOL%2003\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    abr 2026 - nov 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en8\/GEICO 160-E\/ROCSAN        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Eva Guerra<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en8\/GEICO 160-E\/ROCSAN\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en8_GEICO%20160-E_ROCSAN\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    mar 2026 - sep 2026                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN29\/GEICO 159-E\/TroFuse-033        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Luis Manso<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cA Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN29\/GEICO 159-E\/TroFuse-033\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN29_GEICO%20159-E_TroFuse-033\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    nov 2025 - jul 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en34\/GEICO 167-E\/BEHOLD ENDOMETRIAL 01\/GSK- 224038        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en34\/GEICO 167-E\/BEHOLD ENDOMETRIAL 01\/GSK- 224038\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en34_GEICO%20167-E_BEHOLD%20ENDOMETRIAL%2001_GSK-%20224038\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    sep 2026 - dic 2028                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en33\/GEICO 188-E\/BEHOLD-Endometrial02        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Pilar Barretina<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en33\/GEICO 188-E\/BEHOLD-Endometrial02\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en33_GEICO%20188-E_BEHOLD-Endometrial02\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    oct 2026 - oct 2028                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 162-E\/ELEVEN        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro Gallego<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"GEICO 162-E\/ELEVEN\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/GEICO%20162-E_ELEVEN\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    sep 2026 - jul 2027                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en35\/GSK 300118        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Fernando G\u00e1lvez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en35\/GSK 300118\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en35_GSK%20300118\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en37\/Symbiotic-GYN-18        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Cristina Mart\u00edn<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en37\/Symbiotic-GYN-18\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en37_Symbiotic-GYN-18\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"start-up\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Start Up            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en36\/GINECO-EN109b        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Pilar Barretina<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Start Up\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en36\/GINECO-EN109b\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en36_GINECO-EN109b\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT en20\/GEICO 124-E\/XPORT-EC-042        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez Fidalgo<\/span>\r\n\r\n                                    <span>CoPI: Lorena Fari\u00f1as<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT en20\/GEICO 124-E\/XPORT-EC-042\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT%20en20_GEICO%20124-E_XPORT-EC-042\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05611931\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT en 13\/GEICO 108-E\/DOMENICA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: M\u00aa Jesus Rubio<\/span>\r\n\r\n                                    <span>CoPI: Pau Guill\u00e9n<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced\/metastatic setting)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT en 13\/GEICO 108-E\/DOMENICA\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT%20en%2013_GEICO%20108-E_DOMENICA\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05201547\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    feb 2023 - jun 2025                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN26\/GEICO 150-E\/ASCENT-GYN-01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Eva Guerra<\/span>\r\n\r\n                                    <span>CoPI: Neus Ferrer Tur<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                \u201cA Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician\u2019s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy\u201d            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-EN26\/GEICO 150-E\/ASCENT-GYN-01\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-EN26_GEICO%20150-E_ASCENT-GYN-01\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06486441\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    ene 2025 - dic 2025                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en23\/GEICO 132-E\/MK 2870        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Pilar Barretina<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en23\/GEICO 132-E\/MK 2870\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en23_GEICO%20132-E_MK%202870\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06132958\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                            <div class=\"study-recruitment\">\r\n                    Reclutamiento<br>\r\n                    -mar 2026                <\/div>\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en10\/GEICO 92-E\/DUO-E        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Marta Gil<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3Trial with Durvalumab-Olaparib in Newly Diagnosed Advanced and Recurrent endometrial cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en10\/GEICO 92-E\/DUO-E\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en10_GEICO%2092-E_DUO-E\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04269200\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en15\/GEICO 111-E\/MK-3475-C93        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en15\/GEICO 111-E\/MK-3475-C93\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en15_GEICO%20111-E_MK-3475-C93\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-003185-12\/IT\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"avanzado\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Endometrio<\/span>\r\n                <span>Avanzado<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en6\/GEICO 93-E\/RUBY        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                    <span>CoPI: Lydia Gaba<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Endometrio\"\r\n                        data-subtype=\"Avanzado\"\r\n                        data-name=\"ENGOT-en6\/GEICO 93-E\/RUBY\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/endometrio\/avanzado\/ENGOT-en6_GEICO%2093-E_RUBY\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03981796\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"otros\"\r\n     data-subtipo=\"quirurgico\"\r\n     data-estado=\"reclutamiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Otros<\/span>\r\n                <span>Quir\u00fargico<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Reclutamiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            Parola        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: B. D\u00edaz Feijoo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Reclutamiento\"\r\n                        data-type=\"Otros\"\r\n                        data-subtype=\"Quir\u00fargico\"\r\n                        data-name=\"Parola\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/otros\/quirurgico\/Parola\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03386734\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"otros\"\r\n     data-subtipo=\"quirurgico\"\r\n     data-estado=\"seguimiento\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Otros<\/span>\r\n                <span>Quir\u00fargico<\/span>\r\n            <\/div>\r\n            <div class=\"study-state\">\r\n                Seguimiento            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT cx4\/GEICO 130Q\/SENTICOL III        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Zapardiel<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL            <\/div>\r\n        \r\n    <\/div>\r\n\r\n    \r\n        <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                                        <a href=\"#\"\r\n                        class=\"centros_hospitalarios ver-hospitales\"\r\n                        data-mdb-toggle=\"modal\"\r\n                        data-mdb-target=\"#modalInvestigaciones\"\r\n                        data-state=\"Seguimiento\"\r\n                        data-type=\"Otros\"\r\n                        data-subtype=\"Quir\u00fargico\"\r\n                        data-name=\"ENGOT cx4\/GEICO 130Q\/SENTICOL III\"\r\n                        data-hospitals=\"https:\/\/www.geicogroup.com\/wp-content\/plugins\/ensayos_clinicos\/ensayos\/hospitales\/otros\/quirurgico\/ENGOT%20cx4_GEICO%20130Q_SENTICOL%20III\"\r\n                        >\r\n                            Ver hospitales                            <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\">\r\n                                <use href=\"#icon-flecha\"><\/use>\r\n                            <\/svg>\r\n                    <\/a>\r\n                \r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03386734\" target=\"_blank\" rel=\"noopener\">\r\n                       Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n\r\n                    <\/div>\r\n            \r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov40\/GEICO 71-R\/Expression VI        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: P. Barretina<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Caroline meets HANNA \u2013 Holistic Analysis of LoNgterm-survival with OvariaNCAncer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 66-O\/OLATRA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: I. Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase II studyofOlaparib as maintenanceTherapyafter response totrabectedin-pegylatedliposomaldoxorubicin in recurrentovarian carcinoma.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03470805\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov25\/GEICO 48-O\/PAOLA-1        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB \u2013 IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02477644\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 29-O\/INOVATION        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01379989\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT OV27\/GEICO 52-O\/MORAB        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov26\/GEICO 54-O\/PRIMA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02655016\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 37-O\/NOVA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Y. Garc\u00eda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico fase II de quimioterapia neoadyuvante con o sin Bevacizumab en pacientes con c\u00e1ncer de ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 31-O\/NOVA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: JM. Del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                F III, mantenimiento con niraparib vs placebo en reca\u00edda platino sensible.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT ov21\/GEICO 39-O\/SOLO-2        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                F III Olaparib vs placebo de mantenimiento tras reca\u00edda platino-sensible.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03470805\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 30-Q\/DESKTOP III        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Poveda \/ S. Mart\u00ednez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                F III cirug\u00eda o no en la reca\u00edda platino sensible.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01166737\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 33-O\/PENELOPE        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                F III QT +\/- pertuzumab en platino-resistente.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01684878\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 42-R\/ROSE        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio retrospectivo sobre tratamiento del c\u00e1ncer de ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 44-R\/RETRO-ROC        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: I. Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio post-autorizaci\u00f3n observacional restrospectivo y multic\u00e9ntrico de la combinaci\u00f3n con trabectedina y doxorubicinaliposomalpegilada (DLP) en c\u00e1ncer de ovario recidivante.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02394015\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            C\u00d3DIGO DE ENSAYO CL\u00cdNICO: GEICO 1302 - ENGOT OV 11 - Array 162-311        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: I. Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician\u2019s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            C\u00d3DIGO DE ENSAYO CL\u00cdNICO: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: JM. Del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-OV-2b\/TRINOVA 3\/GEICO-1201        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: JM. Del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                TRINOVA \u2013 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            MM-121\/GEICO 1202        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez, Andr\u00e9s Redondo, JM. Rubio, A. Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant\/ Refractory Advanced Ovarian Cancers.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            NCIC-OV 21\/GEICO-0902        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: I. Romero, J. Ponce<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de Fase II-III de quimioterapia intraperitoneal (IP) m\u00e1s intravenosa (IV) frente a carboplatino m\u00e1s Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirug\u00eda citoreductora \u00f3ptima posterior a quimioterapia intravenosa neoadyuvante.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 1001-CATUMAXOMAB        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidaci\u00f3n de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisi\u00f3n completa cl\u00ednica.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            AGO-OVAR 12\/GEICO 1003        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: JM. Del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de fase III, multic\u00e9ntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinaci\u00f3n con carboplatino y paclitaxel comparado con placebo en combinaci\u00f3n con carboplatino y paclitaxel en pacientes con c\u00e1ncer de ovario avanzado.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 1002        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico fase II no controlado, multic\u00e9ntrico y prospectivo para determinar el beneficio cl\u00ednico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-\u03b1 y \u03b2 y C-Kit), en pacientes con c\u00e1ncer de ovario avanzado platino resistentes.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ICON-6\/GEICO 1101        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico multic\u00e9ntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinaci\u00f3n con quimioterapia basada en platino y como agente \u00fanico en terapia de mantenimiento, en mujeres con c\u00e1ncer de ovario que han reca\u00eddo m\u00e1s de 6 meses tras la finalizaci\u00f3n de un tratamiento de primera l\u00ednea basado en platino.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            AURELIA\/GEICO 0904        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                AURELIA: Ensayo cl\u00ednico de fase III multic\u00e9ntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinaci\u00f3n con quimioterapia frente a quimioterapia sola en pacientes con c\u00e1ncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0901\/AGO-OVAR 16        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: JM del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con c\u00e1ncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado despu\u00e9s de la quimioterapia de primera l\u00ednea.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0905-OCTAVIA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0802\/HECTOR-PHASE III-2006        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez, A. Santaballa<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Topotec\u00e1n m\u00e1s carboplatino frente al tratamiento est\u00e1ndar (paclitaxel m\u00e1s carboplatino o gemcitabina m\u00e1s carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0804-R        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: B. Ojeda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Base de datos de Bevacizumab en reca\u00eddas de C\u00e1ncer de Ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0801-T        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio retrospectivo de biomarcadores en C\u00e1ncer Epitelial de Ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0803-R        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Feasibility and toxicity of a modified outpatient regimen of intravenous\/ intraperitoneal chemotherapy (IV\/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0701\/ICON-7        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Cervantes<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio aleatorizado del \u201cGynaecologic Cancer InterGroup\u201d, de dos grupos, multic\u00e9ntrico para a\u00f1adir bevacizumab a la quimioterapia est\u00e1ndar (carboplatino y paclitaxel) en pacientes que sufren c\u00e1ncer epitelial de ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0702-T\/TOPO IIA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Determinaci\u00f3n de la expresi\u00f3n de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0703\/MIMOSA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Casado<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico multic\u00e9ntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ov\u00e1rico tras respuesta completa a la quimioterapia de la 1\u00aa l\u00ednea.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0104        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0101        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: MA. Izquierdo, A. Cervantes<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico de fase III para evaluar el tratamiento con la combinaci\u00f3n cisplatino m\u00e1s topotec\u00e1n seguido de paclitaxel m\u00e1s carboplatino frente a paclitaxel m\u00e1s carboplatino como tratamiento de primera l\u00ednea en mujeres con un diagn\u00f3stico reciente de c\u00e1ncer epitelial de ovario avanzado.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0103        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: B. Ojeda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio fase II, con Gemcitabina en infusi\u00f3n prolongada en pacientes con c\u00e1ncer epitelial de ovario avanzado resistentes a platino            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO CO22        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: A. Casado<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Validaci\u00f3n por GEICO de CAELYX en pacientes con c\u00e1ncer epitelial de ovario.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0199        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo cl\u00ednico fase II randomizado (con valoraci\u00f3n de calidad de vida) de carboplatino frente a la combinaci\u00f3n de taxol y carboplatino en pacientes con reca\u00edda de c\u00e1ncer de ovario platino-sensible.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 0299\/EORTC 55981\/NSGO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: MA. Izquierdo, JM del Campo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo Cl\u00ednico aleatorizado de Paclitaxel \/ Epirubicina \/ Carboplatino en combinaci\u00f3n (TEC) vs Paclitaxel \/ Carboplatino (TC) en el tratamiento de mujeres con c\u00e1ncer de ovario avanzado.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov60\/GEICO 98-O\/Ramp 201        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                    <span>CoPI: Alejandro P\u00e9rez Fidalgo<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 2 Study of VS-6766 (Dual RAF\/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03740165\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov66\/GEICO 104-O\/AXLerate-OC        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Pilar Barretina<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Double-Blind, Adaptive, Placebo\/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04729608\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 55-O\/ROLANDO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez Fidalgo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03161132\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov20\/GEICO 30-Q\/DESKTOP III        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01166737\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov11\/GEICO 40-O\/MILO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ignacio Romero<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized Phase III MEK152 vs chemo Low Grade Serous Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02101788\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov38\/GEICO 62-O\/OReO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03106987\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov21\/GEICO 39-O\/SOLO-2        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01874353\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 105-O        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: M\u00aa Jes\u00fas Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov25\/GEICO 48-O\/PAOLA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez \/ Ra\u00fal Marquez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB \u2013 IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02477644\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov39\/GEICO 63-O\/IMAGYN 050        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Yolanda Garc\u00eda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III\/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03038100\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov26\/GEICO 54-O\/PRIMA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02655016\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov29\/GEICO 58-O\/ATALANTE        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02891824\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov34\/GEICO 65-O\/AGO-OVAR 2.29        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                    <span>CoPI: Pilar Barretina<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Atezolizumab in combination with Bevacizumab +\/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer \u2013 a randomised trial            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov41\/GEICO 69-O\/ANITA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) &gt;6 months            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov46\/GEICO 76-O\/DUO-O        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: M\u00aa. Jes\u00fas Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov44\/GEICO 77-O\/FIRST        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                    <span>CoPI: Lydia Gaba<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-Cx6\/GEICO 73-C        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 2 Trial of TisotumabVedotin (HuMax\u00ae-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-CX1\/GEICO 43-O        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: MJ Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg\/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02009579\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 61-C\/AIM2CERV        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase 3 of ADX11-001 administered following chemoradiation as adjuvant treatment for HRLACC.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02853604\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 46-O\/CECILIA        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Fase II carbo-paclitaxel-bevacizumab en primera l\u00ednea del carcinoma de c\u00e9rvix persistente, recurrente o diseminado.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GOG-0240\/GEICO-0903        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo en Fase III aleatorizado de Cisplatino m\u00e1s Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan m\u00e1s Paclitaxel, con y sin Bevacizumab, en carcinoma de c\u00e9rvix en estadio IVB, recurrente o persistente.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 2005\/01        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: MJ Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de c\u00e1ncer de c\u00e9rvix persistente o recidivante tras fracaso de tratamiento de primera l\u00ednea con derivados del platino.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx9\/GEICO 72-C\/EMPOWER Cx-1 \/\/ REGENERON        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator&#039;s choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03257267\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx1\/GEICO 43-C        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: M\u00aa. Jes\u00fas Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg\/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02009579?term=cx1&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"cervix\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de C\u00e9rvix<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-cx10\/GEICO 68-C\/BEATcc        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=NCT03556839\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-EN3\/GEICO 64-E\/PALEO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: C. Mendiola<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02730429\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 59-RT\/Retro LMS        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: MJ Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO P02868\/GEIS 7        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Poveda<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Ensayo Fase IV-II de Temozolamida en esquema de administraci\u00f3n oral continua en el tratamiento de los Sarcomas Ginecol\u00f3gicos.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en5\/GEICO 67-E\/SIENDO        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Alejandro P\u00e9rez Fidalgo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05611931\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            GEICO 70-E\/WI 231461 AVE-IIG-03        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Jose M\u00aa Piulats<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT\/METASTATIC ENDOMETRIAL CANCER            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05611931\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en7\/GEICO 75-E\/ATTEND        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Pilar Barretina<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced\/recurrent endometrial cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03603184\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en9\/GEICO 83-E\/LEAP-001        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: M\u00aa Jes\u00fas Rubio<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003009-24\/DE\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"endometrio\"\r\n     data-subtipo=\"cerrados\"\r\n     data-estado=\"cerrado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cerrado<\/span>\r\n                <span>C\u00e1ncer de Endometrio<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-en11\/GEICO 94-E\/MK\u20103475\u2010B21        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Pilar Barretina<\/span>\r\n\r\n                                    <span>CoPI: Lorena Fari\u00f1as<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 3, Randomized, Double\u2010Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High\u2010Risk Endometrial Cancer After Surgery With Curative Intent            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                                    <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-003424-17\/CZ\" target=\"_blank\" rel=\"noopener\">\r\n                        Ver m\u00e1s                    <\/a>\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cancelados\"\r\n     data-estado=\"cancelado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cancelado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov73\/GEICO 123-O\/LUPPA-1        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Luis Manso<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cancelados\"\r\n     data-estado=\"cancelado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cancelado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT-ov71\/GEICO 121-O\/UP-NEXT        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Antonio Gonz\u00e1lez<\/span>\r\n\r\n                                    <span>CoPI: Marga Romero<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cancelados\"\r\n     data-estado=\"cancelado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cancelado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT OV75\/ GEICO 128-O\/INNOVATE 5        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Margarita Romero Mart\u00edn<\/span>\r\n\r\n                                    <span>CoPI: Gloria Marquina<\/span>\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cancelados\"\r\n     data-estado=\"cancelado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cancelado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT gyn2\/GEICO 97-O\/BOUQUET        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Andr\u00e9s Redondo<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<div class=\"layout_contenidos\"\r\n     data-tipo=\"ovario\"\r\n     data-subtipo=\"cancelados\"\r\n     data-estado=\"cancelado\">\r\n\r\n    <div class=\"study-header\">\r\n                    <div class=\"study-type\">\r\n                <span>Cancelado<\/span>\r\n                <span>C\u00e1ncer de Ovario<\/span>\r\n            <\/div>\r\n        \r\n        <div class=\"study-title\">\r\n            ENGOT ov79\/GEICO 134-O\/STRO-002-GM3 (REFRaME-01)        <\/div>\r\n\r\n        <div class=\"study-authors\">\r\n                            <span>PI: Ana Oaknin<\/span>\r\n\r\n                                \r\n                    <\/div>\r\n\r\n                    <div class=\"study-description\">\r\n                A Phase 2\/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator\u2019s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)            <\/div>\r\n        \r\n    <\/div>\r\n\r\n            <div class=\"study-footer\">\r\n            <div class=\"container-study-buttons\">\r\n                            <\/div>\r\n        <\/div>\r\n\r\n    \r\n<\/div>\r\n<\/div><\/div><div class=\"modal fade\" id=\"modalInvestigaciones\" tabindex=\"-1\" aria-labelledby=\"title_modal_investigaciones\" aria-hidden=\"true\">\r\n    <div class=\"modal-dialog modal-xl modal-dialog-centered\">\r\n        <div class=\"modal-content\">\r\n\r\n            <div class=\"modal-header\">\r\n                <h5 id=\"title_modal_investigaciones\" class=\"modal-title\"><\/h5>\r\n                <button type=\"button\" class=\"btn-close\" data-mdb-dismiss=\"modal\" aria-label=\"Cerrar\"><\/button>\r\n            <\/div>\r\n\r\n            <div id=\"body_modal_investigaciones\" class=\"modal-body w-100\"><\/div>\r\n\r\n            <div class=\"modal-footer modal-centered\">\r\n                <button id=\"boton_cerrar_investigaciones\" type=\"button\" class=\"btn-close-modal\" data-mdb-dismiss=\"modal\">Cerrar<\/button>\r\n            <\/div>\r\n\r\n        <\/div>\r\n    <\/div>\r\n<\/div>\r\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Clinical Trials<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9853,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-profesional.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-9855","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/comments?post=9855"}],"version-history":[{"count":27,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855\/revisions"}],"predecessor-version":[{"id":11070,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855\/revisions\/11070"}],"up":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9853"}],"wp:attachment":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/media?parent=9855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}